Biopharmaceutical company Zai Lab Ltd. raised HK$6.61 billion ($825 million) on its secondary listing in Hong Kong Monday, as it became the latest U.S.-listed Chinese company to start trading closer to home amid growing Wall Street wariness.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
